Home » Stocks » FGEN » Company

FibroGen, Inc. (FGEN)

Stock Price: $18.57 USD -0.24 (-1.28%)
Updated Apr 9, 2021 4:00 PM EDT - Market closed
After-hours: $18.68 +0.11 (0.59%) Apr 9, 7:56 PM
FibroGen, Inc.
Country United States
IPO Date Nov 14, 2014
Industry Biotechnology
Sector Healthcare
Employees 599
CEO Enrique Conterno

Contact Details

Address:409 Illinois St
San Francisco, California 94158-2509
United States
Phone 415 978 1200

Stock Information

Ticker Symbol FGEN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 0000921299
CUSIP Number 31572Q808
ISIN Number US31572Q8087
Employer ID 77-0357827

Company Description

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs.

The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy.

The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Key Executives

James A. SchoeneckChairman
Pat CotroneoChief Financial Officer
Dr. Elias KouchakjiSenior Vice President of Clinical Development, Drug Safety and Pharmacovigilance
Christine L. ChungSenior Vice President of China Operations
Enrique A. ConternoChief Executive Officer and Director
Dr. Barry A. BerkowitzFounder
Dr. Michael J. MartinelliSenior Vice President of Technical Development
Dr. Percy Carter M.B.A., Ph.D.Chief Scientific Officer
Karen L. BergmanVice President of Investor Relations and Corporate Communications
Michael D. Lowenstein J.D., Ph.D.Chief Legal Officer